Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Mattiello

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Briefings in Bioinformatics|October 3, 2017
A broken promise: microbiome differential abundance methods do not control the false discovery rateStijn Hawinkel, Federico Mattiello, Luc Bijnens, et al.
Contemporary Clinical Trials|November 20, 2019
An efficient Bayesian platform trial design for borrowing adaptively from historical control data in lymphomaJames Normington, Jiawen Zhu, Federico Mattiello, et al.
Bioinformatics (Oxford, England)|May 7, 2016
A web application for sample size and power calculation in case-control microbiome studiesFederico Mattiello, Bie Verbist, Karoline Faust, et al.
American Journal of Hematology|August 21, 2020
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapyFarheen Mir, Federico Mattiello, Andrew Grigg, et al.
Blood|January 29, 2021
Treatment dependence of prognostic gene expression signatures in de novo follicular lymphomaChristopher R Bolen, Federico Mattiello, Michael Herold, et al.
Blood Advances|April 17, 2020
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYASarah C Rutherford, Michael Herold, Wolfgang Hiddemann, et al.
Ejhaem|November 29, 2023
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trialsLale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
Leukemia & Lymphoma|July 11, 2022
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial designKristine Broglio, Lale Kostakoglu, Carol Ward, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN StudyBruce D Cheson, Neil Chua, Jiri Mayer, et al.
Ejhaem|July 18, 2022
A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYALale Kostakoglu, Federico Dalmasso, Paola Berchialla, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Briefings in Bioinformatics|October 3, 2017
A broken promise: microbiome differential abundance methods do not control the false discovery rateStijn Hawinkel, Federico Mattiello, Luc Bijnens, et al.
Contemporary Clinical Trials|November 20, 2019
An efficient Bayesian platform trial design for borrowing adaptively from historical control data in lymphomaJames Normington, Jiawen Zhu, Federico Mattiello, et al.
Bioinformatics (Oxford, England)|May 7, 2016
A web application for sample size and power calculation in case-control microbiome studiesFederico Mattiello, Bie Verbist, Karoline Faust, et al.
American Journal of Hematology|August 21, 2020
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapyFarheen Mir, Federico Mattiello, Andrew Grigg, et al.
Blood|January 29, 2021
Treatment dependence of prognostic gene expression signatures in de novo follicular lymphomaChristopher R Bolen, Federico Mattiello, Michael Herold, et al.
Blood Advances|April 17, 2020
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYASarah C Rutherford, Michael Herold, Wolfgang Hiddemann, et al.
Ejhaem|November 29, 2023
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trialsLale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
Leukemia & Lymphoma|July 11, 2022
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial designKristine Broglio, Lale Kostakoglu, Carol Ward, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN StudyBruce D Cheson, Neil Chua, Jiri Mayer, et al.
Ejhaem|July 18, 2022
A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYALale Kostakoglu, Federico Dalmasso, Paola Berchialla, et al.
Pageof 2